Volume 26, Issue 6 (9-2019)
RJMS 2019, 26(6): 44-53 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ardeshiri M, Zia Jahromi N. The effect of Chartine on expression of Pdx1 gene in streptozotocin-induced diabetic rats. RJMS 2019; 26 (6) :44-53
URL: http://rjms.iums.ac.ir/article-1-5612-en.html
URL: http://rjms.iums.ac.ir/article-1-5612-en.html
Shahrekord Branch Islamic Azad University, Shahrekord, Iran , n.zia@iaushk.ac.ir
Abstract: (2868 Views)
Background: Pdx1 is a transcription factor that plays a key role in pancreatic development and regulation of insulin gene expression and the aim of the present study was to evaluate the effect of pregnancy on the treatment of diabetes-induced liver disease and the expression of the Pdx1 gene, an apoptotic gene, and in the event of damage to the anti-apoptotic activity.
Methods: In this experimental study, 42 adult male Wistar rats were randomly divided into 7 healthy control groups, diabetic control, control group, Chartine 150 mg / kg controls, and Three groups received the effective dose of the Chartine (50, 100 and 200 mg / kg). All groups except diabetic control group and control group with streptozotocin chemical injected intraperitoneally. Afterwards, they received a cartilage by gavage for four weeks. At the end, the data were evaluated statistically.
Results: According to the obtained data, it can be concluded that the lowest expression is related to the diabetic group (C) and the highest expression among the groups receiving different doses of the Chartine was related to the dose of 100 (F), and the least relevant dose was 50 (E).
Conclusion: Evidence suggests that increased expression of the Pdx1 gene was not dose-dependent. After the development of diabetes, the patient's severity declined sharply, and after the use of chronitin and metformin, this reduction was some what offset.
Methods: In this experimental study, 42 adult male Wistar rats were randomly divided into 7 healthy control groups, diabetic control, control group, Chartine 150 mg / kg controls, and Three groups received the effective dose of the Chartine (50, 100 and 200 mg / kg). All groups except diabetic control group and control group with streptozotocin chemical injected intraperitoneally. Afterwards, they received a cartilage by gavage for four weeks. At the end, the data were evaluated statistically.
Results: According to the obtained data, it can be concluded that the lowest expression is related to the diabetic group (C) and the highest expression among the groups receiving different doses of the Chartine was related to the dose of 100 (F), and the least relevant dose was 50 (E).
Conclusion: Evidence suggests that increased expression of the Pdx1 gene was not dose-dependent. After the development of diabetes, the patient's severity declined sharply, and after the use of chronitin and metformin, this reduction was some what offset.
References
2. 1. Baynes H. Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Ddiabetes Metabol; 2015.6(5):1-9.
3. 2. Topf JM, Hiremath S. Social media, medicine and the modern journal club. Int Rev Psychiatry; 2015.27(2):147-54.
4. 3. Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics; 2015. 5(10):1122.
5. 4. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circul Res; 2017.121(7):749-70.
6. 5. Falk RH, Alexander KM, Liao R, Dorbala S. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am College Cardiol; 2016.68(12):1323-41.
7. 6. Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, et al. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: morphology matters. Surgery; 2016. 159(3):862-71.
8. 7. Barker JM. Type 1 diabetes-associated autoimmunity: natural history, genetic associations,
9. and screening. J Clin Endocrinol Metabol; 2006.91(4):1210-7.
10. 8. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management: Elsevier Health Sciences; 2015.
11. 9. Yoon JW, Austin M, Onodera T, Notkins AL. Virus-induced diabetes mellitus: isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New Engl J Med; 1970.300(21):1173-9.
12. 10. Al-Rowais NA. Herbal medicine in the treatment of diabetes mellitus. Saudi Med J; 2002.23(11):1327-31.
13. 11. Davidson MB, Davidson MB. Diabetes mellitus: diagnosis and treatment: Saunders Philadelphia; 1998.
14. 12. Gajjela S, Chatterjee R, Subba S, Sen A. Prospect of liquid organic manure on organic bitter gourd cultivation. J Pharmacog Phytochem; 2018.7(6):189-93.
15. 13. Desai S, Tatke P. Charantin: An important lead compound from Momordica charantia for the treatment of diabetes. J Pharmacog Phytochem; 2015.3(6):163-6.
16. 14. Dandawate PR, Subramaniam D, Padhye SB, Anant S. Bitter melon: a panacea for inflammation and cancer. Chinese J Natural Med; 2016.14(2):81-100.
17. 15. Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, et al. Ribosome‐inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase‐1 selectively in premalignant and malignant prostate cancer cells. Int J Cancer; 2009.125(4):774-8.
18. 16. Joseph B, Jini D. Antidiabetic effects of Momordica charantia (bitter melon) and its medicinal potency. Asian Pac J Trop Dis; 2013.3(2):93-102.
19. 17. Garau C, Singh J, Cummings E. Beneficial effect and mechanism of action of Momordica charantia in the treatment of diabetes mellitus: a mini review. Int J Diabetes Metabol; 2003.11:46-55.
20. 18. Singh SK. “olypeptide-k” as phytoinsulin: How much and how far. Int J Green Pharm; 2017.11(02).
21. 19. Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S, Hsu WH. Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bullet; 2006.29(6):1126-31.
22. 20. Zar A, Hoseini A, Ahmadi F, Rezaei M. Effects of ginger together with swimming training on blood fat profiles in adult diabetic rats with streptozotocin. Iran J Nutr Sci Food Technol; 2016.11(2):65-74.
23. 21. Zangeneh M. Hematoprotective and Nephroprotective Properties of Ethanolic Extract of Anthemis odontostephana Boiss in Streptozotocin-induced Diabetic Mice. J Med Plants; 2018.17(65):47-60.
24. 22. Kabiri N, Tabandeh MR, Tabatabaie SRF. Beneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation. DARU J Pharm Sci; 2014.22(1):39.
25. 23. Castro AVB, Kolka CM, Kim SP, Bergman RN. Obesity, insulin resistance and comorbidities? Mechanisms of association. Arquivos Brasileiros Endocrinol Metabol; 2014.58(6):600-9.
26. 24. Perfetti R, Zhou J, Doyle MiE, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology; 2000.141(12):4600-5.
27. 25. Soleimani MM, Hashemitabar M, Momeni H, Bahramzadeh S. Effect of metformin on the Pdx-1 gene expression during development of mouse pancreas. Iran J Endocrinol Metabol; 2010.12(3):300-20.
28. 26. Choi KS, Shin JS, Lee JJ, Kim YS, Kim SB, Kim CW. In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract. Biochem Biophysic Res Commun 2005.330(4):1299-305.
29. 27. Richardson H, Campbell S, Smith S, Macfarlane W. Effects of rosiglitazone and metformin on pancreatic beta cell gene expression. Diabetologia; 2006.49(4):685-96.
30. 28. Shih CC, Lin CH, Lin WL. Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract; 2008.81(2):134-43.
31. 29. Vessal M, Hemmati M, Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comparat Biochem Physiol Part C: Toxicol Pharmacol; 2003.135(3):357-64.
32. 30. Kaushik U, Aeri V, Mir SR. Cucurbitacins–an insight into medicinal leads from nature. Pharmacog Rev; 2015.9(17):12.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
